This paper analyzes the impact of the introduction of biosimilar drugs on hospital pharmaceutical expenditure, utilizing cost data from ULSS 5 Polesana as empirical evidence. Through a Budget Impact Analysis conducted on regional DDFF3 and FAROSP data flows (2024-2025 biennium), the study quantifies the savings areas achieved, as well as those missed, relative to the targets set by Azienda Zero at the beginning of the year. The findings demonstrate how proper governance of biosimilars generates allocative efficiency, making it possible to combine compliance with healthcare expenditure ceilings with expanded access to therapies for patients in the region.
Il seguente elaborato analizza l'impatto che ha l'introduzione dei farmaci biosimilari sulla spesa farmaceutica ospedaliera, utilizzando come prova empirica i dati di costo dell'ULSS 5 Polesana. Attraverso una Budget Impact Analysis condotta sui flussi regionali DDFF3 e FAROSP (biennio 2024-2025), lo studio quantifica le aree di risparmio conseguite e non rispetto agli obiettivi prefissati da Azienda Zero all'inizio dell'anno. I risultati dimostrano come una corretta governance dei biosimilari generi efficienza allocativa, permettendo di coniugare il rispetto dei tetti di spesa sanitari con un ampliamento dell'accesso alle terapie per i pazienti del territorio.
Analisi dell'impatto dei farmaci biosimilari sulla spesa farmaceutica ospedaliera: caso studio dell'ULSS 5 Polesana
PADOVAN, TOMMASO
2025/2026
Abstract
This paper analyzes the impact of the introduction of biosimilar drugs on hospital pharmaceutical expenditure, utilizing cost data from ULSS 5 Polesana as empirical evidence. Through a Budget Impact Analysis conducted on regional DDFF3 and FAROSP data flows (2024-2025 biennium), the study quantifies the savings areas achieved, as well as those missed, relative to the targets set by Azienda Zero at the beginning of the year. The findings demonstrate how proper governance of biosimilars generates allocative efficiency, making it possible to combine compliance with healthcare expenditure ceilings with expanded access to therapies for patients in the region.| File | Dimensione | Formato | |
|---|---|---|---|
|
Padovan_Tommaso.pdf
Accesso riservato
Dimensione
1.37 MB
Formato
Adobe PDF
|
1.37 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/115590